Tocilizumab reduces hypercoagulation in COVID-19 – Perspectives from the coagulation and immunomodulation Covid assessment (Coag-ImmCovA) clinical trial

Related articles

1. Lacticaseibacillus rhamnosus attenuates gut-derived uremic toxins in patients with non-dialysis chronic kidney disease, partly through the anti-inflammatory molecules, impacts of innate immunity

   This article has 10 authors:

   1. Asada Leelahavanichkul
   2. Pornpimol Phuengmaung
   3. Thansita Bhunyakarnjanarat
   4. Warerat Kaewduangduen
   5. Pimmada Boonnaj
   6. Pichanan Tengamnuay
   7. Wiwat Chancharoenthana
   8. Somkanya Tungsanga
   9. Suwasin Udomkarnjananun
   10. Somying Tumwasorn

2. Efficacy of colchicine with or without corticosteroids in hospitalized COVID-19 patients: A systematic review and meta-analysis

   This article has 6 authors:

   1. Marisa D. Arthur
   2. Jason Wilson
   3. Enze Cai
   4. JongWon See
   5. Brent M. Peterson
   6. Thushara Galbadage

3. High-Volume Hemodiafiltration: Expanding the Evidence Beyond Randomized Trials—A Critical Perspective on the 2025 EuDial Consensus

   This article has 2 authors:

   1. Stefano Stuard
   2. Franklin W. Maddux